MonoMethyl-p53 (Lys370)抗体;MonoMethyl-p53 (Lys370) Antibody—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using HLA-DPA1 mouse mAb against Raji(1) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using HLA-DPA1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using HLA-DPA1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using HLA-DPA1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human gastric cancer tissues using HLA-DPA1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using HLA-DPA1 mouse mAb with DAB staining.    

  
  

The MonoMethyl-p53 (Lys370) antibody is a specialized tool used to detect p53 protein monomethylated at lysine residue 370. a post-translational modification critical for regulating p53 activity. The tumor suppressor p53 plays a central role in maintaining genomic stability by inducing cell cycle arrest, apoptosis, or DNA repair in response to stress. Post-translational modifications, including methylation, fine-tune p53's stability, localization, and interactions with co-regulators. Lys370 methylation, mediated by methyltransferases like SETD7. has been implicated in modulating p53's transcriptional activity and its binding to negative regulators such as MDM2. This modification may influence p53-dependent responses to oncogenic signals or DNA damage.

The MonoMethyl-p53 (Lys370) antibody is widely employed in cancer research to study p53 regulation in tumorigenesis, particularly in cancers with wild-type p53. It enables detection of this modification via techniques like Western blotting, immunohistochemistry, and immunoprecipitation, aiding investigations into p53's functional dynamics in cell lines, tissues, or patient samples. Studies using this antibody have provided insights into how Lys370 methylation affects p53-mediated tumor suppression, its crosstalk with other modifications (e.g., phosphorylation, acetylation), and its potential as a biomarker or therapeutic target. Researchers frequently apply it in models of colorectal, breast, and lung cancers to explore context-specific regulatory mechanisms. Proper validation with methylation-deficient mutants or enzymatic treatments is essential to ensure specificity in experimental settings.